Recruiting PHASE1 INTERVENTIONAL 4-arm NCT05785754

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Sponsor: DynamiCure Biotechnology

Conditions Advanced or Metastatic Solid Tumors

Interventions DCSZ11 Doxorubicin Pembrolizumab Tebentafusp

Updated 13 times since 2023 Last updated: Jun 23, 2025 Started: Jun 28, 2023 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05785754, this PHASE1 trial focuses on Advanced or Metastatic Solid Tumors and remains actively recruiting participants. Sponsored by DynamiCure Biotechnology, it has been updated 13 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

13 versions recorded

Dec 2025 — Present [monthly]

Recruiting PHASE1
Sep 2025 — Dec 2025 [monthly]

Recruiting PHASE1
Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE1
Dec 2024 — Jul 2025 [monthly]

Recruiting PHASE1
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE1

▶ Show 8 earlier versions

Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Jan 2024 — Apr 2024 [monthly]

Recruiting PHASE1
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE1
Sep 2023 — Dec 2023 [monthly]

Recruiting PHASE1
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jun 2023 — Aug 2023 [monthly]

Not Yet Recruiting PHASE1
Apr 2023 — Jun 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

DynamiCure Biotechnology

Data source: DynamiCure Biotechnology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Baltimore, United States , Bedford Park, Australia , Birmingham, United States , Boston, United States , Buderim, Australia , Busan, South Korea , Clayton, Australia , Columbus, United States , Denver, United States and 22 more locations